In a significant vote of confidence for India’s deep-tech biotech sector, Cellogen Therapeutics has raised ₹20 crore (approximately $2 million) in a fresh funding round. The investment was led by Kotak Alternate Asset Managers, channeling the capital through its specialist Kotak Life Sciences Fund. This infusion is not merely about financial runway, it is about accelerating a mission that could fundamentally alter the landscape of advanced cancer care in the country: making revolutionary cell and gene therapies accessible to the millions who are currently priced out.
The world of oncology has been transformed by Chimeric Antigen Receptor T-cell (CAR-T) therapy, a groundbreaking treatment that re-engineers a patient’s own immune cells to hunt and destroy cancer. Yet, this “living drug” comes with a prohibitive price tag, often running between $500,000 and $700,000 per treatment in Western markets. This places it far beyond the reach of the average Indian patient. Cellogen Therapeutics is tackling this price-access paradox head-on, not just by lowering costs but by building what it believes is a next-generation, more effective therapeutic platform. This new capital is the fuel required to move its promising science from the laboratory toward human clinical trials.
The Science and The Founders: A Mission to Re-engineer Cancer Care
Founded in 2021 by two of the country’s leading medical experts, Dr. Gaurav Kharya and Dr. Tanveer Ahmad, Cellogen Therapeutics is built on a foundation of deep clinical expertise. Dr. Kharya is a renowned pediatric hemato-oncologist and a pioneer in bone marrow transplants, giving the company an unparalleled understanding of the clinical realities and patient needs in treating complex blood cancers and disorders. This is not a technology in search of a problem, but a solution born from decades of first-hand experience on the front lines of patient care.
The company’s core innovation lies in its proprietary CAR-T platform. While conventional first-generation CAR-T therapies are designed to recognize and attack a single protein marker (antigen) on the surface of a cancer cell, this can sometimes lead to treatment evasion or relapse if the cancer cells mutate and stop expressing that specific marker. Cellogen’s approach is more sophisticated. It has developed a bispecific, dual-antigen targeting platform. In simple terms, their engineered T-cells are equipped to look for two different markers on a cancer cell simultaneously. This dual-lock system is designed to create a more robust and lasting attack, significantly reducing the probability of relapse compared to single-antigen therapies.
This technological edge, for which the company secured a patent last year, is central to its strategy. It is not just about creating a more affordable version of an existing therapy, but a scientifically superior one. Prior to this round, Cellogen had already attracted strategic capital from Hyderabad-based Natco Pharma, which acquired a stake of over 5% for ₹15 crore. This early backing from an established pharmaceutical player provided crucial validation of both its scientific platform and its commercial potential.
The Deal: A Strategic Bet on Deep Science
The ₹20 crore investment comes from Kotak Alternate Asset Managers, a firm that has been sharpening its focus on high-potential, science-led ventures. The capital was deployed from its Kotak Life Sciences Fund I (KLSF-I), a vehicle specifically created to back early and growth-stage companies in the life sciences and health-tech domains. The fund, which marked its first close last year at ₹250 crore, is backed by a consortium of family offices, ultra-high-net-worth individuals, and industry veterans.
For Kotak, the investment in Cellogen Therapeutics represents a textbook execution of its thesis. It is a bet on a company with strong, defensible intellectual property, a massive addressable market, and a founding team with unimpeachable domain expertise. Investing in biotech, particularly at this pre-clinical stage, requires a long-term vision and a deep understanding of the scientific and regulatory pathways. Kotak’s commitment signals a growing maturity in the Indian venture ecosystem, where investors are increasingly willing to underwrite complex, deep-science risks for the promise of paradigm-shifting returns and societal impact.
Use of Funds: The Critical Path to Clinical Trials
Cellogen has outlined a clear and disciplined plan for the deployment of this new capital. The funds are earmarked for three critical, capital-intensive pillars that form the bridge from pre-clinical research to human trials.
- Advancing CAR-T Clinical Programs: The primary allocation will go towards the immense preparatory work required for initiating Phase I human clinical trials. This includes finalizing trial designs, securing partnerships, and completing extensive documentation for regulatory submission. The company is already collaborating with the renowned Christian Medical College (CMC) in Vellore, a partnership that will be vital for conducting these trials.
- Strengthening Manufacturing and Regulatory Capabilities: Producing cell therapies is an incredibly complex process. The funds will be used to bolster the company’s GMP (Good Manufacturing Practice) compliant facilities. Ensuring that every batch of engineered cells is safe, pure, and potent is non-negotiable and a major focus for regulatory bodies. This investment will also strengthen the in-house regulatory team to navigate the rigorous approval processes with the Central Drugs Standard Control Organisation (CDSCO).
- Expanding the Gene Therapy Pipeline: Beyond cancer, Cellogen is leveraging its cellular engineering expertise to develop therapies for genetic blood disorders. The capital will help advance its early-stage programs for beta-thalassemia and sickle cell disease, two conditions that are highly prevalent in the Indian population and represent a significant unmet medical need.
_
_
Market Opportunity: Democratizing a Medical Miracle
The core of Cellogen’s investment thesis is its ambition to radically reduce the cost of treatment. The company is aiming to price its CAR-T therapies in the range of $60,000 to $70,000 (approximately ₹50-60 lakh). This represents a nearly 90% reduction from the current costs in the US, transforming it from a treatment for the ultra-wealthy to a viable option for a much broader segment of the population in India and other emerging markets.
The competitive landscape in India, while nascent, is heating up. The most notable player is ImmunoACT, a spin-off from IIT Bombay, which received commercial approval for its CAR-T therapy, NexCAR19, in late 2023. Priced at around ₹30-40 lakh, NexCAR19 has already demonstrated that domestic development can shatter global price barriers. However, it is a single-antigen targeting therapy. Cellogen’s key differentiator will be to prove in clinical trials that its dual-antigen approach leads to better long-term outcomes and lower rates of relapse, justifying a potentially similar price point with the promise of superior efficacy. The market is certainly large enough for multiple players, and technological differentiation will be key to capturing share.
What’s Next: The Road Ahead
With fresh capital in the bank, Cellogen’s immediate and singular focus is on the path to the clinic. The coming months will be dedicated to securing the final regulatory approvals to commence its Phase I human clinical trials. Successfully demonstrating safety and preliminary efficacy in these initial trials will be the single most important milestone in the company’s journey.
The collaboration with CMC Vellore will be instrumental, providing the clinical infrastructure and expertise necessary to execute these complex studies. For Dr. Kharya, Dr. Ahmad, and their team, the scientific hypothesis will soon be put to the ultimate test.
The journey for any deep-tech biotech firm is a marathon, not a sprint. It is fraught with scientific challenges, regulatory hurdles, and immense capital requirements. Yet, the potential reward is revolutionary. If Cellogen Therapeutics succeeds, it will not only build a tremendously valuable enterprise but will also deliver on a profound promise: bringing a medical miracle within reach of the people who need it most.
This funding round is a critical step in that long journey, providing the resources to prove that world-class, life-saving innovation can be both scientifically advanced and radically affordable.
